Antioxidant-based therapies for angiotensin II-associated cardiovascular diseases

Erin G. Rosenbaugh, Krupa K. Savalia, Devika S. Manickam, Matthew C Zimmerman

Research output: Contribution to journalReview article

42 Citations (Scopus)

Abstract

Cardiovascular diseases, including hypertension and heart failure, are associated with activation of the renin-angiotensin system (RAS) and increased circulating and tissue levels of ANG II, a primary effector peptide of the RAS. Through its actions on various cell types and organ systems, ANG II contributes to the pathogenesis of cardiovascular diseases by inducing cardiac and vascular hypertrophy, vasoconstriction, sodium and water reabsorption in kidneys, sympathoexcitation, and activation of the immune system. Cardiovascular research over the past 15-20 years has clearly implicated an important role for elevated levels of reactive oxygen species (ROS) in mediating these pathophysiological actions of ANG II. As such, the use of antioxidants, to reduce the elevated levels of ROS, as potential therapies for various ANG II-associated cardiovascular diseases has been intensely investigated. Although some antioxidant-based therapies have shown therapeutic impact in animal models of cardiovascular disease and in human patients, others have failed. In this review, we discuss the benefits and limitations of recent strategies, including gene therapy, dietary sources, lowmolecular- weight free radical scavengers, polyethylene glycol conjugation, and nanomedicine-based technologies, which are designed to deliver antioxidants for the improved treatment of cardiovascular diseases. Although much work has been completed, additional research focusing on developing specific antioxidant molecules or proteins and identifying the ideal in vivo delivery system for such antioxidants is necessary before the use of antioxidant-based therapies for cardiovascular diseases become a clinical reality.

Original languageEnglish (US)
Pages (from-to)R917-R928
JournalAmerican Journal of Physiology - Regulatory Integrative and Comparative Physiology
Volume304
Issue number11
DOIs
StatePublished - Jun 10 2013

Fingerprint

Angiotensin II
Cardiovascular Diseases
Antioxidants
Renin-Angiotensin System
Reactive Oxygen Species
Therapeutics
Nanomedicine
Free Radical Scavengers
Cardiomegaly
Vasoconstriction
Research
Genetic Therapy
Blood Vessels
Immune System
Animal Models
Heart Failure
Sodium
Hypertension
Technology
Kidney

Keywords

  • Angiotensin
  • Antioxidants
  • Cardiovascular disease
  • Free radical scavengers
  • Oxidative stress
  • Therapy

ASJC Scopus subject areas

  • Physiology
  • Physiology (medical)

Cite this

Antioxidant-based therapies for angiotensin II-associated cardiovascular diseases. / Rosenbaugh, Erin G.; Savalia, Krupa K.; Manickam, Devika S.; Zimmerman, Matthew C.

In: American Journal of Physiology - Regulatory Integrative and Comparative Physiology, Vol. 304, No. 11, 10.06.2013, p. R917-R928.

Research output: Contribution to journalReview article

@article{a5e47fe161cd41ac992c3c97b4d21576,
title = "Antioxidant-based therapies for angiotensin II-associated cardiovascular diseases",
abstract = "Cardiovascular diseases, including hypertension and heart failure, are associated with activation of the renin-angiotensin system (RAS) and increased circulating and tissue levels of ANG II, a primary effector peptide of the RAS. Through its actions on various cell types and organ systems, ANG II contributes to the pathogenesis of cardiovascular diseases by inducing cardiac and vascular hypertrophy, vasoconstriction, sodium and water reabsorption in kidneys, sympathoexcitation, and activation of the immune system. Cardiovascular research over the past 15-20 years has clearly implicated an important role for elevated levels of reactive oxygen species (ROS) in mediating these pathophysiological actions of ANG II. As such, the use of antioxidants, to reduce the elevated levels of ROS, as potential therapies for various ANG II-associated cardiovascular diseases has been intensely investigated. Although some antioxidant-based therapies have shown therapeutic impact in animal models of cardiovascular disease and in human patients, others have failed. In this review, we discuss the benefits and limitations of recent strategies, including gene therapy, dietary sources, lowmolecular- weight free radical scavengers, polyethylene glycol conjugation, and nanomedicine-based technologies, which are designed to deliver antioxidants for the improved treatment of cardiovascular diseases. Although much work has been completed, additional research focusing on developing specific antioxidant molecules or proteins and identifying the ideal in vivo delivery system for such antioxidants is necessary before the use of antioxidant-based therapies for cardiovascular diseases become a clinical reality.",
keywords = "Angiotensin, Antioxidants, Cardiovascular disease, Free radical scavengers, Oxidative stress, Therapy",
author = "Rosenbaugh, {Erin G.} and Savalia, {Krupa K.} and Manickam, {Devika S.} and Zimmerman, {Matthew C}",
year = "2013",
month = "6",
day = "10",
doi = "10.1152/ajpregu.00395.2012",
language = "English (US)",
volume = "304",
pages = "R917--R928",
journal = "American Journal of Physiology - Renal Physiology",
issn = "0363-6127",
publisher = "American Physiological Society",
number = "11",

}

TY - JOUR

T1 - Antioxidant-based therapies for angiotensin II-associated cardiovascular diseases

AU - Rosenbaugh, Erin G.

AU - Savalia, Krupa K.

AU - Manickam, Devika S.

AU - Zimmerman, Matthew C

PY - 2013/6/10

Y1 - 2013/6/10

N2 - Cardiovascular diseases, including hypertension and heart failure, are associated with activation of the renin-angiotensin system (RAS) and increased circulating and tissue levels of ANG II, a primary effector peptide of the RAS. Through its actions on various cell types and organ systems, ANG II contributes to the pathogenesis of cardiovascular diseases by inducing cardiac and vascular hypertrophy, vasoconstriction, sodium and water reabsorption in kidneys, sympathoexcitation, and activation of the immune system. Cardiovascular research over the past 15-20 years has clearly implicated an important role for elevated levels of reactive oxygen species (ROS) in mediating these pathophysiological actions of ANG II. As such, the use of antioxidants, to reduce the elevated levels of ROS, as potential therapies for various ANG II-associated cardiovascular diseases has been intensely investigated. Although some antioxidant-based therapies have shown therapeutic impact in animal models of cardiovascular disease and in human patients, others have failed. In this review, we discuss the benefits and limitations of recent strategies, including gene therapy, dietary sources, lowmolecular- weight free radical scavengers, polyethylene glycol conjugation, and nanomedicine-based technologies, which are designed to deliver antioxidants for the improved treatment of cardiovascular diseases. Although much work has been completed, additional research focusing on developing specific antioxidant molecules or proteins and identifying the ideal in vivo delivery system for such antioxidants is necessary before the use of antioxidant-based therapies for cardiovascular diseases become a clinical reality.

AB - Cardiovascular diseases, including hypertension and heart failure, are associated with activation of the renin-angiotensin system (RAS) and increased circulating and tissue levels of ANG II, a primary effector peptide of the RAS. Through its actions on various cell types and organ systems, ANG II contributes to the pathogenesis of cardiovascular diseases by inducing cardiac and vascular hypertrophy, vasoconstriction, sodium and water reabsorption in kidneys, sympathoexcitation, and activation of the immune system. Cardiovascular research over the past 15-20 years has clearly implicated an important role for elevated levels of reactive oxygen species (ROS) in mediating these pathophysiological actions of ANG II. As such, the use of antioxidants, to reduce the elevated levels of ROS, as potential therapies for various ANG II-associated cardiovascular diseases has been intensely investigated. Although some antioxidant-based therapies have shown therapeutic impact in animal models of cardiovascular disease and in human patients, others have failed. In this review, we discuss the benefits and limitations of recent strategies, including gene therapy, dietary sources, lowmolecular- weight free radical scavengers, polyethylene glycol conjugation, and nanomedicine-based technologies, which are designed to deliver antioxidants for the improved treatment of cardiovascular diseases. Although much work has been completed, additional research focusing on developing specific antioxidant molecules or proteins and identifying the ideal in vivo delivery system for such antioxidants is necessary before the use of antioxidant-based therapies for cardiovascular diseases become a clinical reality.

KW - Angiotensin

KW - Antioxidants

KW - Cardiovascular disease

KW - Free radical scavengers

KW - Oxidative stress

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=84878596688&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878596688&partnerID=8YFLogxK

U2 - 10.1152/ajpregu.00395.2012

DO - 10.1152/ajpregu.00395.2012

M3 - Review article

C2 - 23552499

AN - SCOPUS:84878596688

VL - 304

SP - R917-R928

JO - American Journal of Physiology - Renal Physiology

JF - American Journal of Physiology - Renal Physiology

SN - 0363-6127

IS - 11

ER -